This case study reports that a canine with hepatoid cell carcinoma had a positive health turnaround after one month of biorregulatory therapy, following limited success and adverse effects from metronomic chemotherapy.
This case report describes a 12-year-old male dog with hepatoid cell carcinoma, showing significant health improvement after a month of bioregulatory therapy, including gastroenteropathy resolution, hair regrowth, and restored vision.
May 2018 in “Journal of Clinical Oncology” This study observed that a combination of low-dose cyclophosphamide and vinorelbine appears safe and has promising antitumor activity in patients with metastatic breast cancer resistant to anthracyclines and taxanes, achieving a 44% objective response rate at 6 months with manageable toxicity levels.
This scoping review found that chemotherapy-induced alopecia in breast cancer patients, especially when using anthracycline- and taxane-based regimens, occurs at higher rates and with more persistence than historically reported.
46 citations
,
February 2012 in “Oncology Reports” This review summarizes existing studies on sorafenib, noting its promising effects in some cancers, but also highlights its limitations and potential synergy when combined with other anticancer treatments.